To study the therapeutic effect of DFP‐10825 on peritoneally disseminated gastric cancer, different doses of DFP‐10825 (2.5, 5.0, 10, or 20 μg TS shRNA/mouse/d) were intraperitoneally injected into a MKN45 peritoneally disseminated mouse model twice weekly. This evidence concerns the gene TYMS and gastric cancer.